SynthesisJournal of surgical oncology2025
Neoadjuvant Chemotherapy for Retroperitoneal Sarcoma: A Systematic Review and Meta-Analysis.
Synthesis in Journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Neoadjuvant Chemotherapy for Retroperitoneal Sarcoma: A Systematic Review and Meta-Analysis.Journal of surgical oncology · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionRetroperitoneal sarcoma is a rare malignancy, and surgical resection remains the primary treatment option. While neoadjuvant radiotherapy has shown limited long-term benefits, the role of neoadjuvant chemotherapy in this setting remains uncertain. This study aimed to evaluate the impact of neoadjuvant chemotherapy on survival outcomes in patients with resectable retroperitoneal sarcoma.
methodsA comprehensive search was performed in PubMed, Scopus, the Central Register of Clinical Trials, and Web of Science for studies published up to December 2024. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using a random-effects model, and heterogeneity was assessed using I² statistics. Statistical analyses were conducted using R Software version 4.4.1 (R Foundation for Statistical Computing).
resultsFour retrospective studies were included, comprising a total of 2156 patients with resectable retroperitoneal sarcoma, of whom 361 (16.7%) received neoadjuvant chemotherapy. The analysis showed no significant difference in 5-year overall survival between patients who underwent neoadjuvant chemotherapy and those who did not. A sensitivity analysis, performed after excluding the study contributing most to heterogeneity, revealed a statistically significant 18% higher risk of mortality in patients receiving neoadjuvant chemotherapy (HR 1.18; 95% CI 1.06-1.32). Heterogeneity dropped to I² = 0% in this analysis.
conclusionThese findings suggest that neoadjuvant chemotherapy may be associated with worse survival outcomes, although these results remain exploratory due to the retrospective nature of the included studies and the limited number of available datasets. Ongoing prospective trials, such as the STRASS2 trial, will be critical to further defining the role of neoadjuvant chemotherapy in retroperitoneal sarcoma management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.